Figure 3
From: Identification of triptonide as a therapeutic agent for triple negative breast cancer treatment
SNAI1 expression is induced in TN-resistant HCC1806 cells. (a) Comparisons of parental and TN-resistant HCC1806 cell morphology and growth rate in TN-resistant HCC1806 cells with or without triptonide treatment. Each bar is presented as mean ± SD (n = 3). Magnification, × 200. (b) Mammosphere formation ability of TN-resistant HCC1806 cells compared with parental cells. (**, p < 0.01). (c) mRNA expression of ITGA6, Myc, KLF17, and SNAI1 in TN-resistant HCC1806 cells compared with parental cells. Each bar is presented as mean ± SD (n = 3) (*, p < 0.05. **, p < 0.01, ***, p < 0.001). SNAI1 protein levels were also measured by immunoblotting. (d) Immunoblotting of p-AKT, p-ERK, p-JNK (left panel) in parental and TN-resistant HCC1806 cells. Immunoblotting of SNAI1 and p-JNK or p-ERK in TN-resistant HCC1806 cells treated with the JNK inhibitor SP600126 (10 µM) and the ERK inhibitor U0126 (10 µM).
